Systemic and Local Paracrine Cytokine Therapies Using Transduced Tumor Cells Are Synergistic in Treating Intracranial Tumors

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 405-413

  Thompson, Reid C ^a   Pardoll, Drew M ^a   Jaffee, Elizabeth M ^a   Ewend, Matthew G ^a   Thomas, Matthew C ^a   Tyler, Betty M ^a   Brem, Henry ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; CNS; Cytokine; GM CSF; IL 2

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; GENETIC TRANSDUCTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSFECTION;

EID: 0030322365     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00004     Document Type: Article

References (32)

1. Tepper R, Pattengale P, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989;57:503-12.
2. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
4. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
5. Colombo M, Ferrari G, Stoppacciaro A. Granulocyte colony-stimulating factor gene transfer suppresses tumorgenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-95.
6. Colombo M, Modesti A, Pariani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross talk. Cancer Res 1992;52: 4853-7.
7. Pulaski BA, McAdam AJ, Hunter EK, Biggar S, Lord EM. Interleukin-3 enhances development of tumor-reactive cytotoxic T cells by a CD4-dependent mechanism. Cancer Res 1993;53:2112-7.
8. Karp SE, Farber A, Salo JC, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 1993;150:896-908.
9. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
10. Blankenstein T, Qin Z, Uberla K. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
11. Porgador A, Tzehoval E, Katz A. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppressses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-87.
12. Rollins B, Sunday M. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991; 11:3125-32.
13. Hock H, Dorsch M, Diamantstein T. Interleukin 7 induces CD42+ T cell-dependent tumor rejection. J Exp Med 1991;174:1291-9.
14. Restifo N, Spiess P, Karp S. A non-immunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175:1423-8.
15. Mulligan R. The basic science of gene therapy. Science 1993;260: 926-32.
16. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery 1995;37:1129-45.
17. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993;53:3125-8.
18. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993;259:94-7.
19. Tjuvajev J, Gansbacher B, Desai R, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995;55:1902-10.
20. Inaba K, Steinman R, Pack M, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175: 1157-67.
21. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
22. Steinman R. The dendritic system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-81.
23. Zar J, eds. Biostatistical analysis. Englewood Cliffs, New Jersey: Prentice-Hall, 1984:140-50.
24. Jaffee E, Lazenby A, Meurer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother 1995;18: 1-9.
25. Black P. Brain tumors. N Engl J Med 1991;324:1471-6.
26. Brem H, Pinatadosi S, Burger P, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-12.
27. Hickey W. Migration of hematogenous cells through the blood brain barrier and the initiation of CNS inflammation. Brain Pathol 1991;1:97-105.
28. Wekerle H, Linington C, Lassermann H, Meyermann R. Cellular immune reactivity within the CNS. TINS 1986;271-7.
29. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-8.
30. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993;53:2221-6.
31. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 1994;80:535-40.
32. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat glioma by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909-14.